Core Technologies
Patents
Patents
Intellectual Property (IP) Portfolio
As of July 23, 2025, Gwo Xi Stem Cell holds 120 patents worldwide, protecting its proprietary technologies and strengthening its leadership in the cell therapy industry.
East Asia
101 patents (Taiwan, China, Japan)
Southeast Asia
5 patents (Vietnam, Indonesia, Singapore, Malaysia)
Europe and America
14 patents (United States)
East Asia
Southeast Asia
Europe and America
Core Technology
Core Technology
Core Technology Platform
Nigiro-Med® is a proprietary technology developed by GWOXI, designed to enhance the therapeutic effects of stem cell therapy through unique activation processes that significantly empower stem cells to modulate the microenvironment and reactivate regeneration in damaged tissues and organs. By boosting stem cell functionality, Nigiro-Med® aims to achieve improved clinical outcomes across a broad range of diseases.
1. Mimicking the Microenvironment
2. Developing Proprietary Technologies
3. Transforming Naive Stem Cell into Stem Cell Medicine
The dual regenerative platforms, Nigiro-Med® and Micttake®, rapidly screen effective molecules to form conditioned media for stem cell medicine development.
Press Releases
Press ReleasesNEWS
-
26202509Press ReleasesGWOXI Stem Cell Secures Taiwan Invention Patent for Stem Cell-Derived Composition in Wound Healing -
09202509Press ReleasesGWOXI Stem Cell Expands Cross-Border Collaborations — Engaging Potential Partners in Thailand -
22202508Press ReleasesGWOXI Stem Cell Partners with Malaysia’s Cell 101 to Expand into the Asia-Pacific Regenerative Medicine Market